The Video-Based Exercise Programs in Degenerative Meniscus Tears

November 18, 2025 updated by: Tansu Birinci, Istanbul University - Cerrahpasa

Investigation of the Efficacy of Video-Based Exercise Programs in Degenerative Meniscus Tears

This randomized controlled trial aims to investigate the efficacy of the video-based exercise programs in patients with degenerative meniscus tears.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

To investigate the efficacy of video-based exercise programs, voluntary patients with degenerative meniscus tears aged 40-65 years will be randomly assigned to three groups: the hybrid exercise group (HEG), the video-based exercise (VBE) group, and the standard exercise (SE) group. Interventions will be delivered over 16 sessions (twice a week for 8 weeks). The patients will be assessed at baseline and at the end of the 8-week intervention. Pain during activity, at rest, and at night will be assessed using the Visual Analog Scale (VAS). Active range of motion will be evaluated using a digital goniometer. Isometric muscle strength will be measured with a handheld dynamometer. The Knee Injury and Osteoarthritis Outcome Score (KOOS) will evaluate functional status and symptoms. The Western Ontario Meniscal Evaluation Tool (WOMET) will assess health-related quality of life. Adherence to the exercise program and the Global Rating of Change Scale will be evaluated.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
81

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Bakırkoy
      • Istanbul, Bakırkoy, Turkey (Türkiye), 34147
        • Istanbul University-Cerrahpaşa

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

40 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Being aged between 40 and 65 years
  • Having the degenerative meniscus tear in at least one knee
  • Having body mass index in the range of 18-30 kg/m2
  • Feeling the pain that lasts for at least 2 months
  • Having grade 1 or grade 2 degenerative meniscal tear diagnosed by an orthopedic specialist according to the MRI results
  • Having the activity level is between 1 and 5 according to the Tegner Activity Scale
  • Having access to the internet via a computer or smartphone
  • Having the ability to read and write Turkish

Exclusion Criteria:

  • Having undergone arthroscopic partial meniscectomy surgery due to degenerative meniscal tear
  • Participating in a physiotherapy program for degenerative meniscal tear in the last 12 weeks
  • Have received steroid injections in the last 6 months
  • Accompanying conditions such as injury to the surrounding ligaments, congenital anomaly in the affected knee, coxarthrosis and spinal stenosis
  • Presence of any systemic disorder that may affect assessment parameters
  • Failure to cooperate with assessments
  • Any vision or hearing problem that would prevent them from adapting to the assessment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: The Video-based exercise (VBE) group
Each subject in the video-based exercise group (only video-based intervention) will receive a treatment protocol consisting of stretching, strengthening, and functional exercises for the knee and hip.
Other: The video-based exercise (VBE)
An 8-week exercise program will be implemented as part of the conservative treatment for degenerative meniscal tears. The physiotherapist will prepare an instructional video that provides a detailed explanation and demonstration of each exercise. Patients will watch this video at home and perform the exercises according to the video instructions.
Active Comparator: The standard exercise (SE) group
Each subject in the standard exercise group (only clinic-based intervention) will receive a treatment protocol consisting of stretching, strengthening, and functional exercises for the knee and hip.
Other: The standard exercise (SE)

An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.

An exercise program will be performed at the clinic.
Experimental: The hybrid exercise (HE) group
Each subject in the hybrid exercise group (video-based and clinical-based interventions) will receive a treatment protocol consisting of stretching, strengthening, and functional exercises for the knee and hip.
Other: The hybrid exercise (HE)
An 8-week exercise program will be implemented as part of the conservative treatment for degenerative meniscal tears using a hybrid telerehabilitation model. For the home-based component, the physiotherapist will prepare an instructional video that includes a detailed description and demonstration of each exercise. Patients will watch this video at home and perform the prescribed exercises by following the instructions provided in the video. In addition to the home program, patients will also participate in supervised exercise sessions conducted in the clinical setting.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Knee Injury and Osteoarthritis Outcome Score (KOOS)
Time Frame: Baseline
Short-term and long-term symptoms and function will be assessed with the Knee injury and Osteoarthritis Outcome Score (KOOS) that is developed as an extension of the WOMAC Osteoarthritis Index. The score is a percentage score from 0 to 100, 0 representing extreme problems and 100 representing no problems.
Baseline

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Visual Analogue Scale (VAS)
Time Frame: Baseline
Pain intensity will be measured using the visual analogue scale (VAS). The participants will be asked to indicate their perceived pain at rest, during activity and at night on the 10 cm line between no pain and terrible pain. The score will be determined by measuring the distance on 10 cm line using a ruler. The higher scores indicate an higher level of pain.
Baseline
Knee Injury and Osteoarthritis Outcome Score (KOOS)
Time Frame: At the end of 8-week intervention
Short-term and long-term symptoms and function will be assessed with the Knee injury and Osteoarthritis Outcome Score (KOOS) that is developed as an extension of the WOMAC Osteoarthritis Index. The score is a percentage score from 0 to 100, 0 representing extreme problems and 100 representing no problems.
At the end of 8-week intervention
Visual Analogue Scale (VAS)
Time Frame: After 8-week intervention
Pain intensity will be measured using the visual analogue scale (VAS). The participants will be asked to indicate their perceived pain at rest, during activity and at night on the 10 cm line between no pain and terrible pain. The score will be determined by measuring the distance on 10 cm line using a ruler. The higher scores indicate an higher level of pain.
After 8-week intervention
Active Range of Motion
Time Frame: Baseline
Active knee range of motion including flexion and extension will be measured described by the American Academy of Orthopaedic Surgeons (AAOS) using a digital goniometer.
Baseline
Active Range of Motion
Time Frame: At the end of 8-week intervention
Active knee range of motion including flexion and extension will be measured described by the American Academy of Orthopaedic Surgeons (AAOS) using a digital goniometer.
At the end of 8-week intervention
Muscle Strength
Time Frame: Baseline
Isometric muscle strength will be measured with a handheld dynamometer for knee flexors and extensors. The process will be repeated three times in each direction, with the average value recorded.
Baseline
Muscle Strength
Time Frame: At the end of the 8-week intervention
Isometric muscle strength will be measured with a handheld dynamometer for knee flexors and extensors. The process will be repeated three times in each direction, with the average value recorded.
At the end of the 8-week intervention
Western Ontario Meniscal Evaluation Tool (WOMET)
Time Frame: Baseline
The health-related quality of life related to degenerative meniscal tear will be used with the WOMET, which is a disease-specific tool designed to evaluate health-related quality of life in patients with meniscal pathology. The WOMET contains sixteen items addressing three domains: nine items addressing physical symptoms; four items addressing disabilities due to sports, recreation, work, and lifestyle; and three items addressing emotions. The best and least symptomatic score is 0, and the highest and most symptomatic score possible is 1600.
Baseline
Western Ontario Meniscal Evaluation Tool (WOMET)
Time Frame: At the end of the 8-week intervention
The health-related quality of life related to degenerative meniscal tear will be used with the WOMET, which is a disease-specific tool designed to evaluate health-related quality of life in patients with meniscal pathology. The WOMET contains sixteen items addressing three domains: nine items addressing physical symptoms; four items addressing disabilities due to sports, recreation, work, and lifestyle; and three items addressing emotions. The best and least symptomatic score is 0, and the highest and most symptomatic score possible is 1600.
At the end of the 8-week intervention

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Global Rating of Change
Time Frame: At the end of 8-week intervention
The Global Rating of Change is a single-item self-report measure used to assess the participant's perceived overall change following the intervention. At the end of the 8-week intervention, participants will be asked to rate how their current condition compares to their condition before the treatment.
At the end of 8-week intervention
Adherence to Exercise Programs
Time Frame: Throughout the 8-week intervention period
Adherence to the video-based exercise program will be monitored using daily participant-completed exercise logs and verified by weekly video submissions demonstrating the performance of selected exercises. The physiotherapist will directly monitor adherence to the clinic-based exercise program.
Throughout the 8-week intervention period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Istanbul University - Cerrahpasa

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Tansu Birinci, PhD, PT, Istanbul University - Cerrahpasa

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 1, 2022

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 1, 2025

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 5, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 28, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 28, 2022

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 4, 2022

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 21, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 18, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 107

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings